What is HC Wainwright’s Estimate for SWTX FY2024 Earnings?

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) – Equities researchers at HC Wainwright lowered their FY2024 earnings per share (EPS) estimates for SpringWorks Therapeutics in a research report issued on Tuesday, November 12th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($3.03) for the year, down from their prior forecast of ($2.83). HC Wainwright currently has a “Buy” rating and a $74.00 target price on the stock. The consensus estimate for SpringWorks Therapeutics’ current full-year earnings is ($3.17) per share. HC Wainwright also issued estimates for SpringWorks Therapeutics’ Q4 2024 earnings at ($0.59) EPS, Q1 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.23) EPS, Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at $0.11 EPS and FY2025 earnings at ($0.65) EPS.

Other equities analysts have also issued research reports about the stock. JPMorgan Chase & Co. boosted their price objective on shares of SpringWorks Therapeutics from $64.00 to $68.00 and gave the company an “overweight” rating in a research report on Wednesday, September 4th. Wedbush reiterated an “outperform” rating and issued a $77.00 price target on shares of SpringWorks Therapeutics in a report on Thursday, November 7th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $68.17.

SpringWorks Therapeutics Trading Down 0.3 %

SpringWorks Therapeutics stock opened at $36.45 on Friday. The stock has a market cap of $2.71 billion, a PE ratio of -9.39 and a beta of 0.79. The stock has a 50-day moving average price of $32.70 and a 200 day moving average price of $37.07. SpringWorks Therapeutics has a 52 week low of $19.61 and a 52 week high of $53.92.

SpringWorks Therapeutics (NASDAQ:SWTX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.03. SpringWorks Therapeutics had a negative return on equity of 48.21% and a negative net margin of 203.09%. The firm had revenue of $49.10 million during the quarter, compared to the consensus estimate of $53.28 million. During the same period in the previous year, the firm posted ($1.27) EPS. The company’s quarterly revenue was up 4810.0% compared to the same quarter last year.

Hedge Funds Weigh In On SpringWorks Therapeutics

A number of institutional investors have recently added to or reduced their stakes in SWTX. First Horizon Advisors Inc. raised its stake in SpringWorks Therapeutics by 47.9% during the second quarter. First Horizon Advisors Inc. now owns 1,183 shares of the company’s stock worth $45,000 after acquiring an additional 383 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its holdings in SpringWorks Therapeutics by 21.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,686 shares of the company’s stock worth $87,000 after acquiring an additional 474 shares during the period. Allspring Global Investments Holdings LLC bought a new position in shares of SpringWorks Therapeutics during the 2nd quarter valued at about $123,000. CANADA LIFE ASSURANCE Co grew its position in SpringWorks Therapeutics by 20.3% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,465 shares of the company’s stock worth $220,000 after buying an additional 754 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of SpringWorks Therapeutics during the 3rd quarter valued at $147,000.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.